Nanocrystals in Cancer Theranostics: Recent Developments
暫譯: 癌症治療診斷中的奈米晶體：近期發展
Mukherjee, Sudip, Madamsetty, Vijay Sagar, Reddy, Rakesh Chandra
商品描述
Nanocrystals have been established as an important cancer diagnosis and therapeutic tool due to their ability to deliver poorly soluble drugs with sustained release, low toxicity, and flexibility of administration. In this book, the importance and current status of nanocrystals in cancer therapy are presented, along with challenges, and future prospects.
The book focuses on several therapies of nanocrystals, including anticancer, immunotherapy, radiotherapy, biotheranostics, targeted therapy, photothermal, and photodynamic. Further, different imaging and diagnostics using nanocrystals are mentioned, including magnetic resonance imaging (MRI), computed tomography (CT), biosensing, and luminescence. Finally, the limitations and potential solutions of nanocrystals in the field of cancer theranostics are also discussed.
商品描述(中文翻譯)
奈米晶體因其能夠持續釋放難溶性藥物、低毒性及靈活的給藥方式，而被確立為重要的癌症診斷和治療工具。本書介紹了奈米晶體在癌症治療中的重要性和現狀，以及面臨的挑戰和未來展望。
本書專注於奈米晶體的幾種治療方法，包括抗癌、免疫療法、放射療法、生物治療診斷、靶向治療、光熱療法和光動力療法。此外，還提到使用奈米晶體的不同成像和診斷技術，包括磁共振成像（MRI）、電腦斷層掃描（CT）、生物感測和發光。最後，還討論了奈米晶體在癌症治療診斷領域的限制及潛在解決方案。
作者簡介
Dr Sudip Mukherjee: Sudip Mukherjee, PhD, MRSC, is an assistant professor at the School of Biomedical Engineering at the Indian Institute of Technology, BHU (IIT BHU). Dr Mukherjee completed his PhD from CSIR-IICT, Hyderabad, India in 2017 followed by postdoctoral position at Rice University, USA in 2022. His present research interests include the development of advanced biomaterials for cell therapy and drug/gene delivery in diabetes, cancer theranostics, angiogenesis, and immunomodulatory applications. He is member of the Royal Society of Chemistry, UK and AACR, USA. He has published 67 publications, 5 books, 12 book chapters, 15 patents. He serves as an associate editor for the BMC Cancer and Frontiers in Chemistry.
Dr. Vijay Sagar Madamsetty obtained his Ph.D. in chemical science from the Academy of Scientific and Innovative Research (AcSIR), India. With a fervent dedication to pioneering research in nanomedicine spanning 15 years, he embarked on his journey at the Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT). Currently, he is a senior scientist at PolyaRNA Therapeutics in Cambridge, Massachusetts, USA. Dr. Madamsetty's career highlights include his tenure at CSL Seqirus, where he focused on the development of SamRNA-LNP-based nano vaccines targeting influenza diseases. Presently, his focus has shifted towards advancing mRNA-LNP-based vaccines and therapeutics.
Dr. Rakesh C Reddy Meka is a Scientist, with over 15 years of academic & industrial research experience. Special expertise in Immunology, Cell and gene therapy, vaccine development and Nanotechnology. Experience in Cell based assay development techniques with substantial experience in cell and molecular biology, in-vitro, and in-vivo techniques. Involved in the COVID vaccine development project (COVAXIN) and CAR T therapy products. He published peer reviewed articles in RSC, Elsevier, and ACS publications.
Lipi Pradhan is a research scholar presently pursuing her Ph.D. degree in the School of Biomedical Engineering, IIT BHU, Varanasi. She has earned her M.Sc. in Zoology from the Department of Zoology, Ranchi University. Her research interests involved designing cell-based therapy for treating rare genetic disorders and green synthesis of nanoparticles for various biomedical applications.
Devyani Yenurkar is a Prime Minister's Research Fellow (PMRF) in the School of Biomedical Engineering at the Indian Institute of Technology IIT(BHU). She received her master's degree in pharmacy (Pharmaceutics) from SNDT University, Mumbai. Her present interest in research includes work with nanomaterials for their potential applications in the field of blood anticoagulation and thrombosis.
Sumit Manna completed his B.Sc. and M.Sc. in Human Physiology from the University of Calcutta, West Bengal. Currently, he is a research scholar pursuing his Ph.D. degree in the School of Biomedical Engineering at IIT (BHU), Varanasi. His research work focuses on the development of cell-based therapies for the treatment of genetic disorders.
Durba Banerjee is currently pursuing her Ph.D. in School of Biomedical Engineering at IIT BHU Varanasi, where her research is dedicated to cell- based therapies for tissue regeneration and internal wound healing. She holds a Master's a degree in Biotechnology, from Gautam Buddha University, Greater Noida
作者簡介(中文翻譯)
蘇迪普·穆克吉博士： 蘇迪普·穆克吉，博士，MRSC，是印度理工學院BHU（IIT BHU）生物醫學工程學院的助理教授。穆克吉博士於2017年在印度海得拉巴的CSIR-IICT完成博士學位，並於2022年在美國萊斯大學擔任博士後研究員。他目前的研究興趣包括開發用於細胞療法和藥物/基因傳遞的先進生物材料，應用於糖尿病、癌症治療診斷、血管生成和免疫調節等領域。他是英國皇家化學學會和美國癌症研究協會的成員。他已發表67篇論文、5本書、12章書籍和15項專利。他擔任《BMC癌症》和《化學前沿》的副編輯。
維賈伊·薩加爾·馬丹塞提博士在印度科學與創新研究學院（AcSIR）獲得化學科學博士學位。憑藉對納米醫學開創性研究的熱情，他在印度科學與工業研究委員會-印度化學技術研究所（CSIR-IICT）開始了他的研究之旅。目前，他是美國麻薩諸塞州劍橋的PolyaRNA Therapeutics的高級科學家。馬丹塞提博士的職業亮點包括在CSL Seqirus的任期，專注於針對流感疾病的SamRNA-LNP基礎納米疫苗的開發。目前，他的研究重點已轉向推進mRNA-LNP基礎的疫苗和治療方法。
拉克什·C·雷迪·梅卡博士是一位科學家，擁有超過15年的學術和工業研究經驗。專長於免疫學、細胞和基因療法、疫苗開發和納米技術。在細胞基礎檢測技術的開發方面擁有豐富的經驗，並在細胞和分子生物學、體外和體內技術方面有相當的專業知識。參與了COVID疫苗開發項目（COVAXIN）和CAR T療法產品的研究。他在RSC、Elsevier和ACS出版物上發表了同行評審的文章。
莉比·普拉丹目前是印度理工學院BHU（IIT BHU）生物醫學工程學院的研究學者，正在攻讀博士學位。她在印度朗奇大學獲得了動物學碩士學位。她的研究興趣包括設計細胞基礎療法以治療罕見遺傳疾病，以及為各種生物醫學應用進行綠色合成納米顆粒。
德維亞尼·耶努卡爾是印度理工學院BHU（IIT BHU）生物醫學工程學院的總理研究獎學金獲得者（PMRF）。她在孟買的SNDT大學獲得了藥學（製藥學）碩士學位。她目前的研究興趣包括納米材料在血液抗凝和血栓形成領域的潛在應用。
蘇米特·曼納在印度西孟加拉的加爾各答大學完成了人類生理學的學士和碩士學位。目前，他是印度理工學院BHU（IIT BHU）生物醫學工程學院的研究學者，正在攻讀博士學位。他的研究工作專注於開發用於治療遺傳疾病的細胞基礎療法。
杜爾巴·班納吉目前在印度理工學院BHU（IIT BHU）生物醫學工程學院攻讀博士學位，她的研究專注於用於組織再生和內部傷口癒合的細胞基礎療法。她擁有來自大哥達佛大學的生物技術碩士學位。
